Clinical Trial

AI-Guided Sarcopenia Risk Assessment and Detection

Study acronym: SARC-AI
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Sarcopenia, the age-related decline in muscle mass and function, is a major contributor to frailty, disability, and mortality in older adults. Current diagnostic tools assess muscle quantity or function separately and lack predictive biomarkers, limiting early detection and personalized management. This study proposes an AI-driven framework that integrates multimodal physiological, metabolic, and functional data with wearable sensor monitoring to improve sarcopenia risk assessment and guide individualized interventions. In Phase 1, we will analyze a large retrospective dataset of 3,500 adults to identify early predictors of sarcopenia and develop a machine learning-based risk stratification model. Phase 2 will test a 12-week personalized exercise and nutrition intervention in 120 participants, using real-time sensor data and AI-guided adjustments to optimize outcomes. This integrative approach aims to advance early detection, precision intervention, and long-term muscle health in aging populations.
Trial Details
NCT Number NCT07426159
Lead Sponsor Tel Aviv University
Conditions Sarcopenia, Age-related Muscle Loss
Enrollment 120 participants
Start Date 2026-02-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-23